

Enhanced pricing and volume prop growth

We are optimistic about Marico (MRCO IN) due to its robust potential for double-digit sales growth in the medium term, supported by strategic price hikes, improved direct distribution, and strong performance in its Foods and Premium Personal Care segments. Furthermore, as its new business verticals expand, there is an upside potential for margins in the long term, strengthening our positive outlook. We revise MRCO to **Accumulate** from Buy as the stock has run-up 5% in the past month, with TP unchanged at INR 752 on 50x FY27E P/E as we roll-forward.

Pricing actions aid strong revenue growth: Q3 net sales rose 15.4% YoY to INR 27.9bn, in line with expectations, driven by a 17% domestic business growth and volume improvement to 6% (from 5% in Q2). *Parachute* grew 15% in value and 3% in volume, absorbing a 1% impact from a key price-point adjustment. *Saffola* edible oil saw low single-digit volume growth and a 24% value surge due to pricing actions amid rising vegetable oil costs. Value-added hair oils (VAHO) declined 2% YoY due to market sluggishness and competition, though mid and premium segments grew 3%. Foods expanded 31% YoY, led by strong *Saffola* oats growth, achieving an ARR of >INR 10bn. International business grew 16% in constant currency. MRCO expects high-teen consolidated revenue growth in Q4, led by pricing adjustments, including an additional 5% *Parachute* price hike, and steady domestic volume gains.

Growth businesses scaling in-line: Project SETU, which aims to expand direct outlet reach, has successfully extended its presence to 11 states, yielding promising initial results. Furthermore, the new digital-first portfolio has exceeded expectations, achieving an ARR of over INR 6bn in Q3. In the domestic market, the combined revenue share from Foods and Premium Personal Care, including Digital-first brands, reached ~21% in 9M, with a target of surpassing 25% by FY27. The rapid scaling of these portfolios has been accompanied by a notable shift in their profitability in the past few years, emphasizing profitable growth focus of the diversification strategy.

Near-term pressure on margins; long-term story intact: EBITDA margin contracted 210bps YoY to 19.1%, in-line with our expectations. While MRCO is on track to achieve double-digit revenue growth in the consolidated business for FY25, higher input costs, particularly in copra and vegetable oil, are expected to exert temporary pressure on margins in the near term. Management remains confident in maintaining stable margins for Q4 and anticipates FY25 margins to be ~20%. Despite the short-term challenges, the long-term outlook remains positive, with expected margin expansion driven by improvements in the Foods and digital-first portfolio, a favorable product mix, and focus on premiumization as the business continues to scale.

Revise to Accumulate with TP of INR 752: We remain positive on MRCO as it will deliver robust sales/EBITDA CAGR of 10%/9.5% in FY24-27E. We cut our FY26E/FY27E earnings marginally by 1-2% by to factor in lower margin and revise to **Accumulate** from Buy with TP unchanged at INR 752 on 50x (unchanged) FY27E P/E.

Key Financials

YE March	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR mn)	97,640	96,530	107,130	118,081	128,411
YoY (%)	2.6	(1.1)	11.0	10.2	8.7
EBITDA (INR mn)	18,100	20,260	21,623	24,035	26,565
EBITDA margin (%)	18.5	21.0	20.2	20.4	20.7
Adj PAT (INR mn)	13,020	14,810	15,789	17,683	19,678
YoY (%)	6.3	13.7	6.6	12.0	11.3
Fully DEPS (INR)	10.1	11.5	12.2	13.7	15.3
RoE (%)	36.4	38.8	37.8	35.9	34.2
RoCE (%)	44.0	44.8	43.8	42.4	40.9
P/E (x)	66.5	58.4	54.8	49.0	44.0
EV/EBITDA (x)	47.1	42.2	39.1	34.9	31.2

Note: Pricing as on 31 January 2025; Source: Company, Elara Securities Estimate

1 February 2025


Rating: Accumulate
Target Price: INR 752
Upside: 12%
CMP: INR 671
As on 31 January 2025

Key data

Key dulu	
Bloomberg	MRCO IN
Reuters Code	MRCO.NS
Shares outstanding (mn)	1295
Market cap (INR bn/USD mn)	869/10,027
Enterprise Value (INR bn/USD mn)	862/9,953
Avg daily volume 3M (INR mn/USD mn)	1,479/17
52 week high/low	720/486
Free float (%)	41

Note: as on 31 January 2025; Source: Bloomberg

Price chart



Shareholding (%)	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25
Promoter	59.4	59.3	59.2	59.1
% Pledged	0.1	0.1	0.1	0.1
FII	25.5	24.6	24.9	23.4
DII	10.2	11.4	11.3	12.9
Others	4.9	4.7	4.6	4.6
Source: BSE				

Price performance (%)	3M	6M	12M
Nifty	(2.9)	(5.8)	8.2
Marico	4.8	(0.5)	27.1
NSE Mid-cap	(4.3)	(8.9)	10.6
NSE Small-cap	(9.1)	(11.6)	5.5

Source: Bloomberg

Amit Purohit

Building Materials, FMCG, Paints +91 22 6164 8594 amit.purohit@elaracapital.com

Associates Rohit Harlikar Vidhi Puj





Financials (YE March)

Income statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Revenue	97,640	96,530	107,130	118,081	128,411
EBITDA	18,100	20,260	21,623	24,035	26,565
Less: Depreciation & Amortisation	1,550	1,580	1,660	1,741	1,821
EBIT	16,550	18,680	19,963	22,295	24,744
Less: Interest Expense	560	730	720	720	720
Add: Other Income	1,440	1,420	1,519	1,629	1,753
PBT	17,430	19,370	20,762	23,204	25,777
Less Taxes	4,210	4,350	4,663	5,211	5,789
Reported PAT	13,220	15,020	16,099	17,993	19,988
Minority Interest	200	210	310	310	310
Reported PAT after Minority Interest	13,020	14,810	15,789	17,683	19,678
Adjusted PAT	13,020	14,810	15,789	17,683	19,678
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	1,290	1,290	1,290	1,290	1,290
Reserves	36,700	37,030	44,021	51,857	60,697
Minority Interests	1,570	3,370	3,370	3,370	3,370
Borrowings	4,750	3,830	3,830	3,830	3,830
Deferred Tax (Net)	320	2,110	2,110	2,110	2,110
Total Liabilities	44,630	47,630	54,621	62,457	71,297
Gross Block	31,150	37,180	38,380	39,580	40,780
Less: Accumulated depreciation	8,690	9,940	11,612	13,353	15,174
Net Block	22,460	27,240	26,768	26,227	25,606
Capital work in progress	670	440	320	320	320
Investments	10,960	6,020	6,020	6,020	6,020
Cash	7,560	9,430	17,442	25,309	34,360
Net working capital	2,980	4,500	4,071	4,580	4,991
Total Assets	44,630	47,630	54,621	62,457	71,297
Cash flow statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Operating cash flow	16,250	14,870	17,879	18,914	21,089
Operating cash flow Less: Capex	16,250 6,690	14,870 6,130	17,879 1,068	18,914 1,200	
					21,089 1,200 19,889
Less: Capex	6,690	6,130	1,068	1,200	1,200
Less: Capex Free cash flow to firm	6,690 9,560	6,130 8,740	1,068 16,811	1,200 17,714	1,200 19,889
Less: Capex Free cash flow to firm Investing cash flow	6,690 9,560 (9,370)	6,130 8,740 (1,190)	1,068 16,811 (1,068)	1,200 17,714 (1,200)	1,200 19,889 (1,200)
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow	6,690 9,560 (9,370) (5,110)	6,130 8,740 (1,190) (11,810)	1,068 16,811 (1,068) (8,799)	1,200 17,714 (1,200) (9,847)	1,200 19,889 (1,200) (10,838)
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash	6,690 9,560 (9,370) (5,110) 1,770	6,130 8,740 (1,190) (11,810) 1,870	1,068 16,811 (1,068) (8,799) 8,012	1,200 17,714 (1,200) (9,847) 7,867	1,200 19,889 (1,200) (10,838) 9,051
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis	6,690 9,560 (9,370) (5,110) 1,770	6,130 8,740 (1,190) (11,810) 1,870	1,068 16,811 (1,068) (8,799) 8,012	1,200 17,714 (1,200) (9,847) 7,867	1,200 19,889 (1,200) (10,838) 9,051
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%)	6,690 9,560 (9,370) (5,110) 1,770 FY23	6,130 8,740 (1,190) (11,810) 1,870 FY24	1,068 16,811 (1,068) (8,799) 8,012 FY25E	1,200 17,714 (1,200) (9,847) 7,867 FY26E	1,200 19,889 (1,200) (10,838) 9,051 FY27E
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1)	1,068 16,811 (1,068) (8,799) 8,012 FY25E 11.0	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9	1,068 16,811 (1,068) (8,799) 8,012 FY25E 11.0 6.7	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7	1,068 16,811 (1,068) (8,799) 8,012 FY25E 11.0 6.7 6.6	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 12.0	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 12.0 20.4 15.0	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2)	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2)	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4)	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 12.0 20.4 15.0 (0.5)	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5)
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 11.2 12.0 20.4 15.0 (0.5) 35.9	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%) ROCE(%)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 11.2 12.0 20.4 15.0 (0.5) 35.9	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%) ROCE(%) Per share data and Valuation ratios	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2 40.9
Less: Capex Free cash flow to firm Investing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%) ROCE(%) Per share data and Valuation ratios Diluted EPS (INR)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 10.1	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 44.8	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 12.2	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 111.3 20.7 15.3 (0.5) 34.2 40.9 (0.5) 34.2 40.9
Less: Capex Free cash flow to firm Investing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%) ROCE(%) Per share data and Valuation ratios Diluted EPS (INR) EPS growth (%)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 44.8 11.5 13.7	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 12.2 6.6	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7 12.0	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2 40.9 15.3 11.3 7.2
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROCE (%) Per share data and Valuation ratios Diluted EPS (INR) EPS growth (%) DPS (INR)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 10.1 6.3 4.5	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 44.8 11.5 13.7 9.5	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 43.8 12.2 6.6 5.8	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7 12.0 6.5	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2 40.9 15.3 11.3 7.2 44.0
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROCE (%) Per share data and Valuation ratios Diluted EPS (INR) EPS growth (%) DPS (INR) P/E ratio (x)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 (0.2) 36.4 44.0 (0.2) 36.4 44.0	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 (0.2) 38.8 44.8 11.5 13.7 9.5 58.4	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 43.8 12.2 6.6 5.8 54.8	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7 12.0 6.5 49.0	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2 40.9 15.3 11.3 7.2 44.0 31.2
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROCE (%) Per share data and Valuation ratios Diluted EPS (INR) EPS growth (%) DPS (INR) P/E ratio (x) EV/EBITDA (x)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 10.1 6.3 4.5 66.5 47.1	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 (11.5 13.7 9.5 58.4 42.2	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 43.8 12.2 6.6 5.8 5.4.8 39.1	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7 12.0 6.5 49.0 34.9	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 111.3 20.7 15.3 (0.5) 34.2 40.9
Less: Capex Free cash flow to firm Investing cash flow Financing cash flow Net change in cash Ratio Analysis Income statement Ratios (%) Revenue growth EBITDA growth PAT growth EBITDA margin Net margin Return and liquidity ratios Net debt/Equity (x) ROE (%) ROCE(%) Per share data and Valuation ratios Diluted EPS (INR) EPS growth (%) DPS (INR) P/E ratio (x) EV/EBITDA (x) EV/Sales (X)	6,690 9,560 (9,370) (5,110) 1,770 FY23 2.6 7.7 6.3 18.5 13.3 (0.2) 36.4 44.0 10.1 6.3 4.5 66.5 4.5 66.5 47.1 8.7	6,130 8,740 (1,190) (11,810) 1,870 FY24 (1.1) 11.9 13.7 21.0 15.3 (0.2) 38.8 44.8 (0.2) 38.8 44.8 11.5 13.7 9.5 58.4 42.2 8.8	1,068 16,811 (1,068) (8,799) 8,012 FY25E 111.0 6.7 6.6 20.2 14.7 (0.4) 37.8 43.8 12.2 6.6 5.8 54.8 39.1 7.9	1,200 17,714 (1,200) (9,847) 7,867 FY26E 10.2 11.2 12.0 20.4 15.0 (0.5) 35.9 42.4 13.7 12.0 6.5 49.0 34.9 7.1	1,200 19,889 (1,200) (10,838) 9,051 FY27E 8.7 10.5 11.3 20.7 15.3 (0.5) 34.2 40.9 15.3 11.3 7.2 44.0 31.2 6.5

We expect sales to see a 10% CAGR in FY24-27E

We expect EBITDA margin to improve to ${\sim}21\%$ by FY27E

Note: Pricing as on 31 January 2025; Source: Company, Elara Securities Estimate

Sales growth aided by sequential volume uptick and

EBITDA margin was impacted by high raw material cost inflation in domestic business

interventions

in

pricing

domestic business

Quarterly financials

YE March (INR mn)	Q3FY25	Q3FY24	YoY (%)	Q2FY25	QoQ (%)	Q3FY25E	Variance (%)
Net Sales	27,940	24,220	15.4	26,640	4.9	27,600	1.2
Operating Expenses	22,610	19,090	18.4	21,420	5.6	22,266	1.5
% of Sales	80.9	78.8		80.4		80.7	
EBITDA	5,330	5,130	3.9	5,220	2.1	5,334	(0.1)
EBITDA Margins (%)	19.1	21.2		19.6		19.3	
Other Income	420	430	(2.3)	820	(48.8)	350	20.0
Interest	130	190		110		190	
Depreciation	440	420		410	7.3	420	4.8
PBT	5,180	4,950	4.6	5,520	(6.2)	5,074	2.1
Tax	1,120	1,090	2.8	1,190	(5.9)	1,217	(8.0)
Effective Tax Rate(%)	21.6	22.0		21.6		24.0	
Minority Interest	70	30.0		100.0		100.0	
Reported PAT	3,990	3,830	4.2	4,230	(5.7)	3,757	6.2
Adjusted PAT	3,990	3,830	4.2	4,230	(5.7)	3,757	6.2
NPM (%)	14.3	15.8		15.9		13.6	


Source: Company, Elara Securities Estimate

Exhibit 1: Key ratios


YE March (%)	Q3FY25	Q3FY24	YoY bps chg	Q2FY25	QoQ bps chg	Q3FY25E	bps variance
Raw material cost	50.5	48.7	178	49.2	129	51.0	(50)
Staff costs	7.4	7.8	(39)	8.0	(59)	7.8	(34)
Advertising expenses	10.5	10.2	33	10.9	(40)	10.2	27
Other expenses	12.5	12.1	39	12.3	21	11.7	82
Effective tax rate	21.6	22.0	(40)	21.6	6	24.0	(237)
Gross margin	49.5	51.3	(178)	50.8	(129)	49.0	50
EBITDA margin	19.1	21.2	(210)	19.6	(52)	19.3	(25)
NPM	14.3	15.8	(153)	15.9	(160)	13.6	67


Source: Company, Elara Securities Estimate

Exhibit 2: Volume growth improved sequentially



Source: Company, Elara Securities Research





Source: Company, Elara Securities Research



Exhibit 4: Segment-wise performance - All segments except VAHO delivered strong growth


Category	Q3FY25 value growth (%)	Q3FY25 volume growth (%)	Market share (%)	Comments
				 Parachute Rigid registered 3% volume growth, after absorbing the ~1% impact of ml-age reduction in one of the key price-point packs (implemented in lieu of a price increase).
Parachute coconut oil	15	3	55 (volume share)	 Volume offtakes grew in high single digit, leading to ~140bps gain in market share on MAT basis.
(PCNO)				 The brand has taken another round of price increase (~5% at brand level) towards the end of this quarter as copra prices are likely to remain firm in the near term.
				 Saffola Edible Oils registered low-single digit volume growth amidst sharp rise in vegetable oil prices.
				• Edible oil posted 24% revenue growth, led by pricing interventions in the past few months.
Saffola	Edible oil: 24 Foods: 31	Edible oil: low single- digit	Oats: 41 (value share)	 Foods posted robust 31% value growth YoY, nearing INR 10bn ARR in Q3. Saffola Oats delivered double-digit growth, while the newer franchises fared healthily.
				 True Elements and plant-based nutrition portfolio of Plix maintained their accelerated growth momentum.
				 Value-added hair oils declined by 2% in value terms, witnessing definitive signs of recovery on a sequential basis.
Value added hair oils (VAHO)	(2)	NA	28 (value share)	 Mid and premium segments fared better (grew 3% in Q3) and drove ~70bps gain in value market share on MAT basis.
				 MRCO expects gradually improving trends ahead on the back of visible ATL investments and brand activations and gradually improving trends in rural consumption sentiment.
			Post wash Leave-on Serums –	 The digital-first brands scaled ahead of expectations to reach INR 6bn in ARR in Q3.
Premium personal care	NA	NA	47% (volume share) hair gels/waxes/creams 52%	 Beardo continued to scale ahead of expectations and is on course to deliver double-digit EBITDA margin this year.
			(volume share)	 Digital-first portfolio is expected to achieve double-digit EBITDA margin by FY27.


Source: Company, Elara Securities Research

Exhibit 5: International business – Strong performance in Bangladesh, MENA and South Africa regions

Geography	Q3FY25 constant- currency (CC) growth (%)	Comments
Bangladesh	20	 Robust growth in core and new franchises; albeit on a soft base.
South East Asia	(1)	Soft quarter amidst sluggish consumption environment and geopolitical issues in Myanmar.
Middle East and North Africa (MENA)	35	 Strong momentum in the MENA region, led by broad-based growth in Egypt and the Gulf region.
South Africa	17	Strong growth in South Africa with both Hair Care and Health Care franchises faring well.

Source: Company, Elara Securities Research





Source: Bloomberg, Company, Elara Securities Estimate

Exhibit 7: Valuation overview

13.7
15.3
50
15.3
752


Source: Elara Securities Estimate

Exhibit 8: Change in estimates

(INR mn)		Earlier			Revised			% Change		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	
Revenue	105,720	117,258	129,420	107,130	118,081	128,411	1.3	0.7	(0.8)	
EBITDA	21,570	24,233	27,054	21,623	24,035	26,565	0.2	(0.8)	(1.8)	
EBITDA margin (%)	20.4	20.7	20.9	20.2	20.4	20.7	(22)	(31)	(22)	
PAT	15,748	17,836	20,058	15,789	17,683	19,678	0.3	(0.9)	(1.9)	
EPS (INR)	12.2	13.8	15.5	12.2	13.7	15.3	0.3	(0.9)	(1.9)	
Rating		Buy			Accumulate					

Source: Elara Securities Estimate

Coverage History



	Date	Rating	Target Price	Closing Price
22	3-Feb-2023	Accumulate	INR 560	INR 494
23	5-May-2023	Buy	INR 590	INR 494
24	2-Jun-2023	Accumulate	INR 603	INR 549
25	28-Jul-2023	Accumulate	INR 623	INR 574
26	29-Jan-2024	Accumulate	INR 580	INR 517
27	6-May-2024	Accumulate	INR 600	INR 530
28	5-Aug-2024	Accumulate	INR 730	INR 672
29	29-Oct-2024	Buy	INR 752	INR 629
30	31-Jan-2025	Accumulate	INR 752	INR 671

Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient of in understanding / evaluating the Proposal. Nothing in this document factor buy or sell to solicitation to buy or sell to securities of companies referred to in this document. Each recipient of this document and transparent recommendation to its client and would be happy to provide any information in response to specific client and sough bey to growide any information in response to specific client and sex expessed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates to any or other business from any company referred to in this Note and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities (India) Private Limited or any of its affiliates to a seaprate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or information on any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intanded in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or bick would and beserve, any such restriction, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or other jurisdiction, where such dis

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited. Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate and compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

The research analyst did not receive compensation from Marico Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Marico Limited

Elara Capital Inc.'s affiliate did not receive compensation from Marico Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Marico Limited in the next 3 months.

Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



India

Elara Securities (India) Private Limited One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500

Sales Team

Europe Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road,

London, NW1 6JZ,

Tel:+44 20 7486 9733

United Kingdom

USA Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501

Asia / Pacific Elara Capital (Asia) Pte.Ltd. One Marina Boulevard, Level 20, Singapore 018989 Tel : +65 6978 4047

Managing Director	Harendra Kumar harendra.kumar@elaracapital.com +91 22 6164 8571
Head of Research	Dr Bino Pathiparampil bino.pathiparampil@elaracapital.com +91 22 6164 8572

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543 India Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558 Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 India, APAC & Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Australia Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567 India & UK Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544 India & US Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570 Corporate Access, Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Conference & Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595 Events

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: <u>investor.grievances@elaracapital.com</u> - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: <u>anand.rao@elaracapial.com</u> - Tel. +91 22 6164 8509